Business Description
CEL-SCI Corporation is a US-based biotechnology company focused on developing treatments that harness the body's own immune system to fight cancer and other serious diseases. Its most advanced therapy, Multikine, has completed large-scale clinical trials as a potential treatment for certain head and neck cancers, and is being commercialized in the Middle East through a partnership with a Saudi Arabian pharmaceutical company. The company is also advancing its LEAPS technology, a patented approach to activating the immune system against a broad range of conditions including infections, autoimmune disorders, and cancer. Founded in 1983 and headquartered in Vienna, Virginia, CEL-SCI continues to develop several early-stage product candidates targeting rheumatoid arthritis.
